Ticker Details
BioCryst Pharmaceuticals, Inc. Biocryst Pharmaceuticals Inc is a pharmaceutical company that designs, optimizes and develops novel small-molecule drugs that block key enzymes involved in the infectious and inflammatory diseases. It has its focus on oral treatments for rare diseases.
IPO Date:	March 4, 1994
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$2.72B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.23 | 3.37%
Avg Daily Range (30 D):	$0.23 | 2.48%
Avg Daily Range (90 D):	$0.27 | 2.89%

Institutional Daily Volume
Avg Daily Volume:	1.64M
Avg Daily Volume (30 D):	4.55M
Avg Daily Volume (90 D):	4.6M

Trade Size
Avg Trade Size (Sh.):	176
Avg Trade Size (Sh.) (30 D):	140
Avg Trade Size (Sh.) (90 D):	141

Institutional Trades
Total Institutional Trades:	4,406
Avg Institutional Trade:	$2.31M
Avg Institutional Trade (30 D):	$3.34M
Avg Institutional Trade (90 D):	$2.83M
Avg Institutional Trade Volume:	.28M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$3.35M
Avg Closing Trade (30 D):	$8.53M
Avg Closing Trade (90 D):	$7.57M
Avg Closing Volume:	405.57K

News

Jun 12, 2026 @ 11:00 AM BioCryst Presents New Clinical Data and Real-World... Source: Biocryst Pharmaceuticals, Inc.

May 6, 2026 @ 11:00 AM BioCryst Reports First Quarter 2026 Financial Resu... Source: Biocryst Pharmaceuticals, Inc.

May 4, 2026 @ 11:00 AM BioCryst Announces European Licensing Agreement wi... Source: Na

Apr 6, 2026 @ 11:00 AM BioCryst Appoints Sandeep M. Menon Chief Research ... Source: Biocryst Pharmaceuticals, Inc.

Mar 4, 2026 @ 12:00 PM BioCryst Reports Inducement Grants Under Nasdaq Li... Source: Globe Newswire

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$-1.73	$-2.98	$1.17
Diluted EPS	$-1.77	$-2.98	$1.13
Revenue	$885.72M	$156.41M	$406.56M
Gross Profit	$865.83M	$151.04M	$397.03M
Net Income / Loss	$-457.98M	$-721.81M	$245.85M
Operating Income / Loss	$-381.84M	$-701.6M	$260.39M
Cost of Revenue	$19.88M	$5.38M	$9.52M
Net Cash Flow	$66.5M	$82.04M	$-9.56M
PE Ratio